12:00 AM
Dec 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GGF2: Phase I started

Acorda began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial evaluating IV GGF2 in about 50 patients. Acorda gained rights...

Read the full 78 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >